Chemoprevention in familial adenomatous polyposis

Best Practice and Research: Clinical Gastroenterology

Volumn 25, Issue 4-5, 2011, Pages 607-622

  Kim, Brian ^a   Giardiello, Francis M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenomas; Celecoxib; Chemoprevention; Curcumin; Eicosapentaenoic acid; Familial adenomatous polyposis; Sulindac

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ASCORBIC ACID; ATORVASTATIN; CALCIUM; CALCIUM CARBONATE; CELECOXIB; CURCUMIN; CYCLOOXYGENASE 2 INHIBITOR; EFLORNITHINE; ERGOCALCIFEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ICOSAPENTAENOIC ACID; INDOMETACIN; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PRAVASTATIN; QUERCETIN; RANITIDINE; ROFECOXIB; SIMVASTATIN; STARCH; SULINDAC; SULINDAC SULFIDE; SULINDAC SULFONE; TIRACOXIB; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; ADENOMATOUS POLYP; ALLERGIC REACTION; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; APPETITE; ARTICLE; BILIRUBIN BLOOD LEVEL; CARDIOTOXICITY; CHEMOPROPHYLAXIS; CLINICAL TRIAL (TOPIC); COLON POLYP; COLORECTAL CANCER; DEFECATION HABIT; DIARRHEA; DIET SUPPLEMENTATION; DIETARY FIBER; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; DUODENUM ULCER; DYSPEPSIA; EPISTAXIS; FAMILIAL POLYPOSIS; GASTRITIS; GASTROINTESTINAL SYMPTOM; GENERALIZED EDEMA; HEARING LOSS; HEART FAILURE; HEART INFARCTION; HUMAN; INDIGESTION; INTESTINE POLYP; INTESTINE ULCER; LEUKOPENIA; LIVER TOXICITY; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; OLIGOSPERMIA; RECTAL MUCOSA EROSION; RECTUM DISEASE; RECTUM POLYP; SIDE EFFECT; SKIN ABSCESS; STOMACH HEMORRHAGE; STOMACH ULCER; STROKE; SUICIDE; TASTE DISORDER; TENESMUS; THROMBOCYTOPENIA; THROMBOSIS; ULCER PERFORATION; UNSPECIFIED SIDE EFFECT; VOMITING;

ADENOMATOUS POLYPOSIS COLI; ANIMALS; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; COLECTOMY; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 82455168269     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2011.08.002     Document Type: Article

References (106)

1. K.W. Kinzler, M.C. Nilbert, L.K. Su, B. Vogelstein, T.M. Bryan, and D.B. Levy Identification of FAP locus genes from chromosome 5q21 Science 253 1991 661 665 (Pubitemid 21917199)
2. H.F.A. Vasen, G. Moslein, A. Alonso, S. Aretz, I. Bernstein, and L. Bertario Guidelines for the clinical management of familial adenomatous polyposis (FAP) Gut 57 2008 704 713 (Pubitemid 351579987)
3. O. Aziz, T. Athanasiou, V.W. Fazio, R.J. Nicholls, A.W. Darzi, and J. Church Meta-analysis of observational studies of ileorectal versus ileal pouch-anal anastomosis for familial adenomatous polyposis Br J Surg 93 2006 407 417
4. I. Heiskanen, and H.J. Jarvinen Fate of the rectal stump after colectomy and ileorectal anastomosis for familial adenomatous polyposis Int J Colorectal Dis 12 1997 9 13 (Pubitemid 27138351)
5. S. Bulow, J. Bjork, I.J. Christensen, O. Fausa, H. Jarvinen, and F. Moesgaard Duodenal adenomatosis in familial adenomatous polyposis Gut 53 2004 381 386 (Pubitemid 38241334)
6. M. Tsujii, and R.N. DuBois Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2 Cell 83 1995 493 501
7. M. Tsujii, S. Kawano, S. Tsuji, H. Sawaoka, M. Hori, and R.N. Dubois Cyclooxygenase regulates angiogenesis induced by colon cancer cells Cell 93 1998 705 716 (Pubitemid 28257578)
8. F.M. Giardiello, G.J.A. Offerhaus, and R.N. DuBois The role of nonsteroidal anti-inflammatory drugs in colorectal cancer prevention Eur J Cancer 31A 1995 1071 1076
9. M. Oshima, J.E. Dinchuk, S.L. Kargman, H. Oshima, B. Hancock, and E. Kwong Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2) Cell 87 1996 803 809 (Pubitemid 26404280)
10. M.F. McEntee, C.H. Chiu, and J. Whelan Relationship of β-catenin and Bcl-2 expression to sulindac-induced regression of intestinal tumors in Min mice Carcinogenesis 20 1999 635 640 (Pubitemid 29151300)
11. T. He, T.A. Chan, B. Vogelstein, and K.W. Kinzler PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs Cell 99 1999 335 345 (Pubitemid 29519912)
12. S.J. Baek, K.S. Kim, J.B. Nixon, L.C. Wilson, and T.E. Eling Cyclooxygenase inhibitors regulate the expression of a TGF- β superfamily member that has proapoptotic and antitumorigenic activities Mol Pharmacol 59 2001 901 908 (Pubitemid 32274020)
13. C. Herrmann, C. Block, C. Geisen, K. Haas, C. Weber, and G. Winde Sulindac sulfide inhibits Ras signaling Oncogene 17 1998 1769 1776 (Pubitemid 28482779)
14. L.A. Stark, K. Reid, O.J. Sansom, F.V. Din, S. Guichard, and I. Mayer Aspirin activates the NF-κB signaling pathway and induces apoptosis in intestinal neoplasia in two in vivo models of human colorectal cancer Carcinogenesis 28 2007 968 976 (Pubitemid 47072180)
15. W. Waddell, and R.W. Loughry Sulindac for polyposis of the colon J Surg Oncol 24 1983 83 87 (Pubitemid 13004158)
16. F.M. Giardiello, S.R. Hamilton, A.J. Krush, S. Piantadosi, L.M. Hylind, and P. Celano Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis N Engl J Med 328 1993 1313 1316 (Pubitemid 23131373)
17. M. Cruz-Correa, L.M. Hylind, K.E. Romans, S.V. Booker, and F.M. Giardiello Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study Gastroenterology 122 2002 641 645 (Pubitemid 34173815)
18. D. Labayle, D. Fischer, P. Vielh, F. Drouhin, A. Pariente, and C. Bories Sulindac causes regression of rectal polyps in familial adenomatous polypois Gastroenterology 101 1991 635 639
19. K.P. Nugent, K.C.R. Farmer, A.D. Spigelman, C.B. Williams, and R.K.S. Phillips Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis Br J Surg 80 1993 1618 1619 (Pubitemid 24007679)
20. F.M. Giardiello, V.W. Yang, L.M. Hylind, A.J. Krush, G.M. Petersen, and J.D. Trimbath Primary chemoprevention of familial adenomatous polyposis with sulindac N Engl J Med 346 2002 1054 1059 (Pubitemid 34984619)
21. W.R. Waddell, G.F. Ganser, E.J. Cersie, and R.W. Loughry Sulindac for polyposis of the colon Am J Surg 157 1989 175 179 (Pubitemid 19041810)
22. J. Rigau, J.M. Pique, E. Rubio, R. Planas, J.M. Tarrech, and J.M. Bordas Effects of long-term sulindac therapy on colonic polyposis Ann Intern Med 115 1991 952 954
23. M.T. Spagnesi, F. Tonelli, P. Dolara, G. Caderni, R. Valanzano, and A. Anastasi Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment Gastroenterology 106 1994 362 366 (Pubitemid 24041212)
24. H. Ishikawa, I. Akedo, T. Suzuki, H. Narahara, and T. Otani Adverse effects of sulindac used for prevention of colorectal cancer J Natl Cancer Inst 89 1997 1381 (Pubitemid 27418031)
25. G. Winde, K.W. Schmid, B. Brandt, O. Muller, and H. Osswald Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis Dis Colon Rectum 40 1997 1156 1169
26. F. Tonelli, R. Valanzano, L. Messerini, and F. Ficari Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer? J Surg Oncol 74 2000 15 20 (Pubitemid 30387215)
27. F. Fernandez-Lopez, R. Conde-Freire, C. Cadarso-Suarez, J. Garcia-Iglesias, J.L. Puente-Dominguez, and J. Potel-Lesquereux Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry Eur J Surg 167 2001 375 381 (Pubitemid 32510157)
28. I. Guldenschuh, R. Hurlimann, A. Muller, R. Ammann, B. Mullhaupt, and Z. Dobbie Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis Dis Colon Rectum 44 2001 1090 1099 (Pubitemid 32758263)
29. T. Matsumoto, S. Nakarmura, M. Esaki, T. Yao, and M. Iida Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis J Gastroenterol Hepatol 21 2006 251 257
30. C. Hirota, M. Iida, K. Aoyagi, T. Matsumoto, S. Tada, and T. Yao Effects of indomethacin suppositories on rectal polyposis in patients with familial adenomatous polyposis Cancer 78 1996 1660 1665 (Pubitemid 26330892)
31. T. Akasu, T. Yokoyama, K. Sugihara, S. Fujita, Y. Moriya, and T. Kakizoe Peroral sustained-release indomethacin treatment for rectal adenomas in familial adenomatous polyposis: a pilot study Hepatogastroenterology 49 2002 1259 1261
32. F.M. Giardiello, R.A. Casero, S.R. Hamilton, L.M. Hylind, J.D. Trimbath, and D.E. Geiman Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis Gastroenterology 126 2004 425 431 (Pubitemid 38182299)
33. H.T. Lynch, A.G. Thorson, and T. Smyrk Rectal cancer after prolonged sulindac chemoprevention Cancer 75 1995 936 938
34. Y. Niv, and G.M. Fraser Adenocarcinoma in the rectal segment in familial polyposis coli is not prevented by sulindac therapy Gastroenterology 107 1994 854 857 (Pubitemid 24265535)
35. F.M. Giardiello, E.W. Sannhake, R.N. Duobois, L.M. Hylind, C.R. Robinson, and W.C. Hubbard Prostaglandin levels in human colorectal mucosa Dig Dis Sci 43 1998 311 316
36. G.A. Piazza, A.K. Rahm, T.S. Finn, B.H. Fryer, H. Li, and A.L. Stoumen Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction Cancer Res 57 1997 2452 2459 (Pubitemid 27255906)
37. G.A. Piazza, D.S. Alberts, L.J. Hixon, N.S. Paranka, H. Li, and T. Finn Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels Cancer Res 57 1997 2909 2915 (Pubitemid 27315038)
38. W.J. Thompson, G.A. Piazza, H. Li, L. Liu, J. Fetter, and B. Zhu Exisulind induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin Cancer Res 60 2000 3338 3342 (Pubitemid 30482142)
39. N. Arber, S. Kuwada, M. Leshno, R. Sjodahl, R. Hultcrantz, and D. Rex Sporadic adenomatous polyp regression with exisulind is effective but toxic: a randomised, double blind, placebo controlled, dose-response study Gut 55 2006 367 373 (Pubitemid 43268275)
40. R. van Stolk, G. Stoner, W.L. Haytone, K. Chan, B. DeYoung, and L. Kresty Phase I trial of exisulind (sulindac dulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis Clin Cancer Res 6 2000 78 89 (Pubitemid 30064979)
41. N.J. Wight, K. Gottesdiener, N.M. Garlick, C.T. Atherton, S. Novak, and B.J. Gertz Rofecosib, a COX-2 inhibitor, does not inhibit human gastric mucosal prostaglandin production Gastroenterology 120 2001 867 873 (Pubitemid 32193184)
42. T.J. Schnitzer, G.R. Burmester, E. Mysler, M.C. Hochberg, M. Doherty, and E. Ehrsam Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial Lancet 364 2004 665 674 (Pubitemid 39140622)
43. N. Arber, C.J. Eagle, J. Spicak, I. Racz, P. Dite, and J. Hajer Celecoxib for the prevention of colorectal adenomatous polyps N Engl J Med 355 2006 885 895 (Pubitemid 44315981)
44. M.M. Bertagnolli, C.J. Eagle, A.G. Zauber, M. Redston, S.D. Solomon, and K.M. Kim Celecoxib for the prevention of sporadic colorectal adenomas N Engl J Med 355 2006 873 884 (Pubitemid 44315980)
45. J.A. Baron, R.S. Sandler, R.S. Bresalier, H. Quan, R. Riddell, and A. Lanas A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131 2006 1674 1682 (Pubitemid 44958508)
46. G. Steinbach, P.M. Lynch, R.K. Phillips, M.H. Wallace, E. Hawk, and G.B. Gordon The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis N Engl J Med 342 2000 1946 1952 (Pubitemid 30419089)
47. P.M. Lynch, G.D. Ayers, E. Hawk, E. Richmond, C. Eagle, and M. Woloj The safety and efficacy of celecoxib in children with familial adenomatous polyposis Am J Gastroenterol 105 2010 1437 1443
48. T. Higuchi, T. Iwama, K. Yoshinaga, M. Toyooka, M.M. Taketo, and K. Sugihara A randomized, double-blind, placebo-controlled trial of the effect of rofecoxib, a selective cyclooxygenase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients Clin Cancer Res 9 2003 4756 4760 (Pubitemid 37323278)
49. T. Iwama, T. Akasu, J. Utsunomiya, and T. Muto Does a selective cyclooxygenase-2 inhibitor (tiracoxib) induce clinically sufficient suppression of adenomas in patients with familial adenomatous polyposis? A randomized double-blind placebo-controlled clinical trial Int J Clin Oncol 11 2006 133 139
50. P. Dolara, G. Caderni, and F. Tonelli Nimesulide, a selective anti-inflammatory cyclooxygenase-2 inhibitor, does not affect polyp number and mucosal proliferation in familial adenomatous polyposis Scand J Gastroenterol 34 1999 1168 (Pubitemid 29533779)
51. A. Hallak, L. Alon-Baron, R. Shamir, M. Moshkowitz, B. Bulvik, and E. Brazowski Rofecoxib reduces polyp recurrence in familial polyposis Dig Dis Sci 48 2003 1998 2002 (Pubitemid 37410090)
52. S.D. Solomon, J.J.V. McMurray, M.A. Pfeffer, J. Wittes, R. Fowler, and P. Finn Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention N Engl J Med 352 2005 1071 1080 (Pubitemid 40365348)
53. J.A. Baron, R.S. Sandler, R.S. Bresalier, A. Lanas, D.G. Morton, and R. Riddell Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial Lancet 372 2008 1756 1764
54. S.D. Solomon, J. Wittes, P.V. Finn, R. Fowler, J. Viner, and M.M. Bertagnolli Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis Circulation 117 2008 2104 2113 (Pubitemid 351572169)
55. ADAPT Research Group Cardiovascular and cerebrovascular events in the randomized, controlled Alzheimter's Disease Anti-Inflammatory Prevention Trial (ADAPT) PLoS Clin Trials 1 2006 e33
56. J.A. Zell, D. Pelot, W.P. Chen, C.E. McLaren, E.W. Gerner, and F.L. Meyskens Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas Cancer Prev Res 2 2009 209 212
57. J.A. Baron, B.F. Cole, R.S. Sandler, R.W. Haile, D. Ahnen, and R. Bresalier A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 2003 891 899 (Pubitemid 36297997)
58. R. Benamouzig, J. Deyra, A. Martin, B. Girard, E. Jullian, and B. Piednoir Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial Gastroenterology 125 2003 328 336 (Pubitemid 36929412)
59. R.F.A. Logan, M.J. Grainge, V.C. Shepherd, N.C. Armitage, and K.R. Muir Aspirin and folic acid for the prevention of recurrent colorectal adenomas Gastroenterology 134 2008 29 38 (Pubitemid 350309319)
60. A. Cassidy, S.A. Bingham, and J.H. Cummings Starch intake and colorectal cancer risk: an international comparison Br J Cancer 69 1994 937 942 (Pubitemid 24140679)
61. J. Burn, D.T. Bishop, P.D. Chapman, F. Elliott, L. Bertario, and M.G. Dunlop A randomized placebo-controlled prevention trial of aspirin and/or resistant starch in young people with familial adenomatous polyposis Cancer Prev Res 4 2011 655 665
62. A.E. Pegg, and P.P. McCann Polyamine metabolism and function Am J Physiol 43 1982 CC2212 CC2221
63. F.M. Giardiello, S.R. Hamilton, L.M. Hylind, V.W. Yang, P. Tamez, and R.A. Casero Ornithine decarboxylase and polyamines in familial adenomatous polyposis Cancer Res 57 1997 199 201 (Pubitemid 27036592)
64. F.L. Meyskens, and E.W. Gerner Development of difluoromethylornitine (DFMO) as a chemoprevention agent Clin Cancer Res 5 1999 945 951 (Pubitemid 29233206)
65. N.D. Nigro, A.W. Bull, and M. Boyd Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil J Natl Cancer Inst 77 1986 1309 1313 (Pubitemid 17005110)
66. K.R. Lawson, N.A. Ignatenko, G.A. Piazza, H. Cui, and E.W. Gerner Influence of K-ras activation on the survival response of Caco-2 cells to the chemopreventive agents sulindac and difluormethylornithine Cancer Epidemiol Biomarkers Prev 9 2000 1155 1162
67. R.F. Jacoby, C.E. Cole, K. Tutsch, M.A. Newton, G. Kelloff, and E.T. Hwak Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos Cancer Res 60 2000 1864 1870 (Pubitemid 30207645)
68. N.A. Ignatenko, D.G. Besselsen, D.E. Stringer, K.A. Blohm-Mangone, H. Cui, and E.W. Gerner Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polposis Nutr Cancer 60 2008 30 35
69. F.L. Meyskens, C.E. McLaren, D. Pelot, S. Fujikawa-Brooks, P.M. Carpenter, and E. Hawk Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial Cancer Prev Res 1 2008 32 38
70. D.L. Earnest, H. Holubec, R.K. Wali, C.S. Jolley, M. Bissonette, and A.K. Bhattacharyya Chemoprevention of azoxymethane-induced colonic carcinogenesis by supplemental dietary ursodeoxycholic acid Cancer Res 54 1994 5071 5074
71. B.Y. Tung, M.J. Emond, R.C. Haggitt, M.P. Bronner, M.B. Kimmey, and K.V. Kowdley Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis Ann Intern Med 134 2001 89 95 (Pubitemid 32096335)
72. D.S. Pardi, E.V. Loftus, W.K. Kremers, J. Keach, and K.D. Lindor Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis Gastroenterology 124 2003 889 893 (Pubitemid 36389790)
73. 3 inhibit aberrant crypt proliferation in the rat azoxymethane model of colon cancer: roles of cyclin D1 and E-cacherin Cancer Epidemiol Biomarkers Prev 11 2002 1653 1662 (Pubitemid 36020020)
74. R.F. Jacoby, C.E. Cole, E.T. Hwak, and R.A. Lubet Ursodeoxycholate/ sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis Gastroenterology 127 2004 838 844 (Pubitemid 39208416)
75. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N Engl J Med 335 1996 1001 1009 (Pubitemid 26338729)
76. T.R. Pedersen, K. Berg, T.J. Cook, O. Faergeman, T. Haghfelt, and J. Kjekshus Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian Simvasatin Survival Study Arch Intern Med 156 1996 2085 2092 (Pubitemid 26346967)
77. J.N. Poynter, S.B. Gruber, P.D.R. Higgins, R. Almog, J.D. Bonner, and H.S. Rennert Statins and the risk of colorectal cancer N Engl J Med 352 2005 2184 2192 (Pubitemid 40727085)
78. Min mice Cancer Res 66 2006 7370 7377 (Pubitemid 44197721)
79. C.P.J. Caygill, and M.J. Hill Fish, n-3 fatty acids and human colorectal and breast cancer mortality Eur J Cancer Prev 4 1995 329 332
80. T. Norat, S. Bingham, P. Ferrari, N. Slimani, M. Jenab, and M. Mazuir Meat, fish, and colorectal cancer risk: the European prospective investigation into cancer and nutrition J Natl Cancer Inst 97 2005 906 916 (Pubitemid 41417942)
81. Min/+ Mice Clin Cancer Res 1 2010 5703 5711
82. G. Calviello, S. Serini, and E. Piccioni n-3 polyunsaturated fatty acids and the prevention of colorectal cancer: molecular mechanisms involved Curr Med Chem 14 2007 3059 3069 (Pubitemid 350226957)
83. Min/+ Mice J Nutr 130 2000 1153 1158 (Pubitemid 30233261)
84. 2 synthesis and cytotoxicity in human colorectal carcinoma cell lines Carcinogenesis 24 2003 385 392 (Pubitemid 36432632)
85. M.D. Boudreau, K.H. Sohn, S.H. Rhee, S.W. Lee, J.D. Hunt, and D.H. Hwang Suppression of tumor cell growth both in nude mice and in culture by n-3 polyunsaturated fatty acids: mediation through cyclooxygenase-independent pathways Cancer Res 61 2001 1386 1391 (Pubitemid 34292561)
86. N.J. West, S.K. Clark, R.K.S. Phillips, J.M. Hutchinson, R.J. Leiscester, and A. Belluzzi Eicosapentaenoic acid reduces rectal polyp number and size in familial adenomatous polyposis Gut 59 2010 918 925
87. R.T. Greenlee, T. Murray, S. Bolden, and P.A. Wingo Cancer statistics CA Cancer J Clin 2000 50 2000 7 33
88. C.V. Rao, A. Rivenson, B. Simi, and B.S. Reddy Chemoprevention of colon carcinogenesis by dietary curcumin, a naturally occurring plant phenolic compound Cancer Res 55 1995 259 266
89. T. Kawamori, R. Lubet, V.E. Steele, G.J. Kelloff, R.B. Kaskey, and C.V. Rao Chemopreventive effect of curcumin, a naturally occurring anti-inflammatory agent, during the promotion/progression stages of colon cancer Cancer Res 59 1999 597 601 (Pubitemid 29076056)
90. N.N. Mahmoud, A.M. Carothers, D. Grunberger, R.T. Bilinski, M.R. Churchill, and C. Martucci Plant phenolics decrease intestinal tumors in an animal model of familial adenomatous polyposis Carcinogenesis 21 2000 921 927 (Pubitemid 30265135)
91. J.T. Piper, S.S. Singhal, M.S. Salameh, R.T. Torman, U.C. Awasthi, and S. Awasthi Mechanisms of anticarcinogenic properties of curcumin: the effect of curcumin on glutathione linked detoxification enzymes in rat liver Int J Biochem Cell Biol 38 1998 445 456 (Pubitemid 28293675)
92. S.M. Plummer, K.A. Holloway, M.M. Manson, R.J.L. Munks, A. Kaptein, and S. Farrow Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signaling complex Oncogene 18 1999 6013 6020 (Pubitemid 29535013)
93. R.A. Sharma, H.R. McLelland, K.A. Hill, C.R. Ireson, S.A. Euden, and M.M. Manson Pharmacodynamic and pharmacokinetic study of oral cucuma extract in patients with colorectal cancer Clin Cancer Res 7 2001 1894 1900 (Pubitemid 32994823)
94. M. Cruz-Correa, D.A. Shoskes, P. Sanchez, Zhao Rhongua, L.M. Hylind, and S.D. Wexner Combination treatment with curcumin and quercetin of adenomas in familial adenomatous polyposis Clin Gastroenterol Hepatol 4 2006 1035 1038 (Pubitemid 44118839)
95. H.J.R. Bussey, J.J. DeCosse, E.E. Deschner, A.A. Eyers, M.L. Lesser, and B.C. Morson A randomized trial of ascorbic acid in polyposis coli Cancer 50 1982 1434 1439 (Pubitemid 12031971)
96. J.J. DeCosse, H.H. Miller, and M.L. Lesser Effect of wheat fiber and vitamins C and E on rectal polyps in patients with familial adenomatous polyposis J Natl Cancer Inst 81 1989 1290 1297 (Pubitemid 19221789)
97. C. Carroll, K. Cooper, D. Papaioannou, D. Hind, H. Pilgrim, and P. Tappenden Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis Clin Ther 32 2010 789 803
98. M.G. Thomas, J.P.S. Thomson, and R.C.N. Williamson Oral calcium inhibits rectal epithelial proliferation in familial adenomatous polyposis Br J Surg 80 1993 499 501 (Pubitemid 23116096)
99. K.P. Nugent, A.D. Spigelman, and R.K. Phillips Life expectancy after colectomy and ileorectal anastamosis for familial adenomatous polyposis Dis Colon Rectum 36 1993 1059 1062 (Pubitemid 23335255)
100. M.H. Wallace, and R.K.S. Phillips Upper gastrointestinal disease in patients with familial adenomatous polyposis Br J Surg 85 1998 742 750 (Pubitemid 28300499)
101. H.S. Debinski, J. Trojan, K.P. Nugent, A.D. Spigelman, and R.K.S. Phillips Effect of sulindac on small polyps in familial adenomatous polyposis Lancet 345 1995 855 856
102. F. Seow-Choen, V. Vijayan, and V. Keng Prospective randomized study of sulindac versus calcium and claciferol for upper gastrointestinal polyps in familial adenomatous polyposis Br J Surg 83 1996 1763 1766 (Pubitemid 26421882)
103. C.S. Richard, T. Berk, B.V. Bapat, G. Haber, Z. Cohen, and S. Gallinger Sulindac for periampullary polyps in FAP patients Int J Colorectal Dis 12 1997 14 18 (Pubitemid 27138352)
104. R.K.S. Phillips, M.H. Wallace, P.M. Lynch, E. Hawk, G.B. Gordon, and B.P. Saunders A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis Gut 50 2002 857 860 (Pubitemid 34539050)
105. M.H. Wallace, A. Forbes, I.G. Beveridge, A.D. Spigelman, A. Hewer, and S. Venitt Randomized, placebo-controlled trial of gastric acid-lowering therapy on duodenal polyposis and relative adduct labeling in familial adenomatous polyposis Dis Colon Rectum 44 2001 1585 1589 (Pubitemid 33126975)
106. L.A.A. Brosens, C.A. Iacobuzio-Donahue, J.J. Keller, S.R. Hustinx, R. Carvalho, and F.H. Morsink Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G → C COX-2 polymorphism Clin Cancer res 11 2005 4090 4096 (Pubitemid 40791573)